Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CHU de Reims
The main objective of this study will be to define the diagnostic sensitivity of a panel of biomarker on the circulating tumor DNA from peripheral blood.
The secondary objectives of this study will be:
* Study the concordance between mutations in circulating tumor DNA and mutations in tumor tissue - Study the associations between mutational profiles and clinical and histological features of melanoma.
* Study the prognostic impact on survival of the identified genetic profile from the circulating tumor DNA
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patient with melanoma confirmed histologically
patient with metastatic melanoma (stage III unresectable or stage IV)
patient consenting to participate to the study
patient enrolled in the national healthcare insurance program
patient older than 18 years
You may not be if
\- Metastatic tumor whose origin is doubtful (uncertain melanoma)
Clareo Health | Molecular Characterization of Advanced Stage Melanoma by Blood Sampling
